<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02607072</url>
  </required_header>
  <id_info>
    <org_study_id>APREMEC-01</org_study_id>
    <nct_id>NCT02607072</nct_id>
  </id_info>
  <brief_title>Aspirin for Prevention of Postsurgical Recurrence and Metastasis in Asian Colorectal Cancer Patients: a Multi-center Randomized Trial</brief_title>
  <acronym>APREMEC</acronym>
  <official_title>Enteric-coated Aspirin for Prevention of Postsurgical Recurrence and Metastasis in Asian Colorectal Cancer Patients (the APREMEC Trial): a Large-scale Multicenter Randomized Double-blind Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Fourth Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Fourth Affiliated Hospital of Anhui Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Evidence of high quality has suggested that acetylsalicylic acid (ASA)/aspirin&#xD;
      effectively reduces colorectal adenoma incidence and recurrence rate, and several randomized&#xD;
      controlled trials (RCTs) strongly indicate its potential to prevent colorectal cancer (CRC)&#xD;
      initiation and progression and to decrease cancer-related mortality. However the role of&#xD;
      aspirin supplied as an adjuvant agent in postsurgical CRC patients remains obscure, and a RCT&#xD;
      is warranted for clarification.&#xD;
&#xD;
      Aim: The APREMEC trial aims to investigate the potential preventative role of enteric-coated&#xD;
      aspirin (100 mg and 200 mg daily) against postsurgical recurrence and metastasis among Asian&#xD;
      CRC patients.&#xD;
&#xD;
      Design: The investigators hypothesize that this large-scale multicenter randomized&#xD;
      double-blind placebo-controlled trial will support that aspirin can reduce recurrence and&#xD;
      metastasis and improve survival in postsurgical non-metastasized CRC patients. The primary&#xD;
      endpoint of this trial is disease-free survival, and the secondary endpoints are 3-year and&#xD;
      5-year overall survival, the interactive effects of lifestyle including smoking and alcohol&#xD;
      ingestion, and adverse event rate. Eligible postoperative patients with non-metastasized CRC&#xD;
      will be randomized in this trial to 100 mg aspirin, 200 mg aspirin or placebo until&#xD;
      recurrence/metastasis, severe adverse event, death, or end of study, after standard adjuvant&#xD;
      therapy. Individuals with peptic ulcer, bleeding tendency, or previous or ongoing treatment&#xD;
      with aspirin or other anticoagulants will be excluded from this trial. Stratification factors&#xD;
      are gender, study center, cancer site, and tumor stage. After randomization, patients will be&#xD;
      followed up with evaluations at a 3-month interval while taking study drug.&#xD;
&#xD;
      Discussion: This study aims at investigation of aspirin's role as an adjuvant agent in&#xD;
      prevention of postsurgical CRC recurrence and metastasis. If results turn out to be positive,&#xD;
      Asian and global CRC patients will be greatly benefited, due to the fact that aspirin is&#xD;
      inexpensive, easily-accessible, and simply-administered, with well know and managed adverse&#xD;
      events.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year disease free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Aspirin 200 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin 200 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin 100 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin 100 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid (ASA)/aspirin 200 mg daily</intervention_name>
    <arm_group_label>Aspirin 200 mg daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid (ASA)/aspirin 100 mg daily</intervention_name>
    <arm_group_label>Aspirin 100 mg daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  This is a double-blind, placebo-controlled, randomized trial investigating aspirin&#xD;
             application in tumor-nodal-metastasis (TNM) stages I-III CRC without metastasis&#xD;
             requiring surgical resection. Patients ≥ 18 years who have their primary tumors (and&#xD;
             metastatic lymph nodes) completely removed with R0 resection margin, and who have&#xD;
             completed standard adjuvant therapy within 3 months without bleeding potential (e.g.,&#xD;
             platelet count ≥ 100 000/mm3) or other contradictions to aspirin will be eligible for&#xD;
             this trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients allergic to aspirin, receiving previous (within 3 months before surgery) or&#xD;
             ongoing treatment with aspirin, other anti-platelet or anticoagulation agent, other&#xD;
             Cox inhibitors, glucocorticoid, or drugs severely interfering with aspirin, with&#xD;
             peptic ulcer, inflammatory bowel disease (e.g., ulcerative colitis and Crohn's&#xD;
             disease), asthma, ischemic heart disease (IHD), class III/IV heart failure (as defined&#xD;
             by the New York Heart Association), stroke, thrombotic event, peripheral vascular&#xD;
             disease, uncontrolled hypertension, gout or severe liver or renal dysfunction, having&#xD;
             undergone coronary artery bypass grafting within 3 months will be excluded from this&#xD;
             trial. Other exclusion criteria are: colorectal non-malignant diseases (e.g., familial&#xD;
             adenomatous polyposis, and adenoma); recurrent CRC; previous colorectal resection;&#xD;
             malignancies other than CRC (excluding non-melanoma skin cancer) within 5 years before&#xD;
             intake initiation; pregnancy or nursing; immunosuppressive therapy within 6 months;&#xD;
             and enrollment in other CRC clinical trials.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lei Huang, PhD, MD, MSc, MBBS</last_name>
    <phone>+49-17680655141</phone>
    <email>lei.huang@dkfz-heidelberg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Fourth Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A-Man Xu, MD, MBBS</last_name>
      <phone>+86-551-65334247</phone>
      <email>amanxu@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>November 15, 2015</study_first_submitted>
  <study_first_submitted_qc>November 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2015</study_first_posted>
  <last_update_submitted>November 16, 2015</last_update_submitted>
  <last_update_submitted_qc>November 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Fourth Affiliated Hospital of Anhui Medical University</investigator_affiliation>
    <investigator_full_name>Lei Huang</investigator_full_name>
    <investigator_title>Chief doctor, PhD, MD, MSc, MBBS</investigator_title>
  </responsible_party>
  <keyword>APREMEC, aspirin, colorectal cancer, adjuvant therapy, recurrence, metastasis, survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

